Safety, Tolerability and Pharmacokinetics of S 95010 After Single Escalating Intravenous Doses in Young Healthy Male Subjects. A Randomised, Doubleblind, Placebo-controlled, Monocentre, First-In-Human Study.
Phase of Trial: Phase I
Latest Information Update: 16 Apr 2018
At a glance
- Drugs MRG-110 (Primary)
- Indications Heart failure; Ischaemia
- Focus Adverse reactions; First in man
- Sponsors Servier
- 27 Mar 2018 Status changed from planning to recruiting, according to a miRagen Therapeutics media release.
- 15 Nov 2017 New trial record
- 08 Nov 2017 According to a miRagen Therapeutics media release, trial initiation is anticipated in the first half of 2018.